Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy™ R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 14 Rue De La République, Suresnes,île-De-France 92150,france
- Phone
- 33 1 55 42 62 00
- co****@****ext.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pharnext.com
- HQ
- Suresnes, Île-de-France
Pharnext Questions
Pharnext's helpline number is 33 1 55 42 62 00
Pharnext's website is pharnext.com
Pharnext's LinkedIn profile is https://fr.linkedin.com/company/pharnext
Pharnext has
20 employees.
View email and phone details for 20
employees at Pharnext.
Pharnext's industry is
Biotechnology Research
Pharnext's top competitors are
Gensight Biologics,
Neovacs,
Medtronic,
Ionctura,
Cellectis,
Ptc Therapeutics, Inc.,
Rocket Pharmaceuticals,
Nanobiotix,
Apellis Pharmaceuticals,
Mithra.
Pharnext's support email address is contact@pharnext.com
Pharnext's categories are Biotechnology Research
Pharnext's founding year is 2007
